The Conversation (0)
February 21, 2023
Nirvana Life Sciences Inc., (CSE:NIRV) ("Nirvana" or the "Company") a Canadian based life sciences company aimed at developing non-addictive chronic pain and addiction treatment products announces that Mr. Chris Hoffmeister has resigned from the Company's Board of Directors. The Company thanks Mr. Hoffmeister for his service over the last 4 years.
About Nirvana Life Sciences
Nirvana Life Sciences Inc. (CSE:NIRV) is an innovator in the emerging Psychedelic space. At Nirvana, we believe that psylocibin derived medicines can play a leading role in reducing the impacts of the opioids crisis and build healthier communities.
For more information visit https://nirvanalifescience.com/
For further information: Bruce Clark, CEO info@nirvanalifescience.com Phone: 604-401-8100
The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release and accepts no responsibility for the adequacy or accuracy hereof.
NIRV:CC
Alert Options
No alert set
INN Article Notification
Alert Option
You will be notified when this event occurs. No additional settings needed.
07 April 2022
Nirvana Life Sciences
Psychedelics for Opioid Addiction Recovery and Pain Management
Psychedelics for Opioid Addiction Recovery and Pain Management Keep Reading...
17 August
The Calmer Co. Secures Exclusive Global Distribution Agreement for Kava Extract Ingredients up to $25 million
Brisbane, Australia - The Calmer Co. International Limited (ASX: CCO), a leading consumer packaged goods company specialising in kava and other natural products that promote relaxation and sleep support, is pleased to announce the execution of an Exclusive Distribution Agreement with a... Keep Reading...
29 July
Psychedelics Market Trends: H1 2026 Review and Forecast
The psychedelic medicine market is moving swiftly from speculative research mode toward an institutional, prescription-oriented framework as federal policy in the US becomes more supportive.President Donald Trump’s April 18 executive order on ibogaine and other psychedelic therapies helped... Keep Reading...
01 May
Medical Cannabis and Psychedelics Reforms Reshaping Mental Health Markets
The landscape for medical cannabis and psychedelic therapies has rapidly shifted in just a few weeks following recent executive actions in the US. Between the formal rescheduling of medical cannabis to Schedule III and an executive order aimed at accelerating mental health treatments, several... Keep Reading...
24 April
Executive Order Sparks New Phase for Psychedelic Biotech, but Risks Remain
On April 18, US President Donald Trump was joined by top health officials in the Oval Office to sign Accelerating Medical Treatments for Serious Mental Illness, an executive order (EO) to expand research into ibogaine. This signals the strongest federal endorsement yet of psychedelic medicine as... Keep Reading...
20 April
Numinus Wellness Responds to Trump Executive Order on Psychedelic Therapies
Company's clinical research operations and therapist training programs directly positioned to support accelerated research and commercialization timelinesNuminus Wellness Inc. (OTC: NUMIF) today acknowledged the Executive Order signed by President Donald J. Trump directing United States federal... Keep Reading...
20 April
Emyria Launches Global Services Platform Targeting International Drug Sponsors
Emyria’s established, world-first, unique national clinical delivery network to drive a new services-led revenue stream focused on global drug sponsors.
Emyria Limited (ASX: EMD) (“Emyria”, or the “Company”), a leader in innovative mental health treatments, is pleased to announce the launch of its Empax Global Partnership Program, a new services platform enabling international drug sponsors to access Emyria’s established clinical delivery... Keep Reading...
Latest News
Interactive Chart
Latest Press Releases
Related News
TOP STOCKS
American Battery4.030.24
Aion Therapeutic0.10-0.01
Cybin Corp2.140.00